Nelson Vergel
Founder, ExcelMale.com
Stendra (Avanafil) is a PDE5 inhibitor approved for erectile dysfunction by FDA on April 27, 2012 and by EMA (Europe) on June 21, 2013. Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc. Auxilium (makers of the testosterone gel Testim) just gained rights to that drug.
The manufacturer claims Stendra works in 15 minutes. The side effects seems to be similar to those of Viagra (sinus stuffiness, facial flushing, etc)
It is estimated that more than 50 percent of men over 40 years of age experience some degree of ED[1]. Prevalence of the condition increases with age and can be caused by a variety of factors, including medications (anti-hypertensives, histamine receptor antagonists); lifestyle (tobacco, alcohol use); diseases (diabetes, cardiovascular conditions, prostate cancer); prostatectomy, and spinal cord injuries. The market opportunity for ED medical treatments continues to grow, with U.S. sales exceeding $2.9 billion in 2012[2]. About one half of men being treated with currently available PDE5 inhibitors are dissatisfied with the results of that treatment and tend to switch among the products in pursuit of better efficacy or less side effects[3].
[1] Andre B. Prevalence and Incidence of Androgen Deficiency in Middle-Aged and Older Men: Estimates from The Massachusetts Male Ageing Study. The Journal of Clinical Endocrinology & Metabolism. 2004; 89(12):5920-5926.
[2] US TRx revenues per Symphony Health
[3] Impact CR Consumer Segmentation, Feb. 2013; Qualitative Market Interviews (n= 722); HCP Research, Primary Interviews, Life Science Strategy Group LLC n= 64, June 2010.
http://online.wsj.com/article/PR-CO-20131011-905164.html
